Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in ...

Liver cancer remains a significant global health challenge and can develop silently in patients who are unaware they have underlying liver disease. To discuss this unmet need in cancer care, CURE sat ...

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together produces a much stronger effect than using either one alone, suggesting a ...

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...

Learn how weight loss, diet changes and regular exercise can help manage — and sometimes reverse — fatty liver disease when caught early.

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Right now, patients with obesity and cirrhosis ...

Liver cancer, primarily hepatocellular carcinoma, originates in the liver, with hepatitis B and C as major risk factors. Diagnosis involves physical exams, blood tests, imaging, and possibly biopsy to ...

More than 30% of people worldwide have metabolic dysfunction–associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease), including 65% of those with type 2 diabetes (T2D) ...

Bausch Health said on Friday its experimental treatment failed to prevent the first clinically visible symptoms of a ...

Fatty liver disease is not restricted to adults, and its incidence in children and adolescents is continuously increasing.

News and commentary from the world of gastroenterology and hepatology ...

Bausch Health Cos. fell after the company said its treatment for a liver condition fell short of its goals in two late-stage trials.